Short Interest in Tema Oncology ETF (NASDAQ:CANC) Declines By 30.4%

Tema Oncology ETF (NASDAQ:CANC) was the target of a large drop in short interest in October. As of October 15th, there was short interest totalling 1,600 shares, a drop of 30.4% from the September 30th total of 2,300 shares. Based on an average trading volume of 3,800 shares, the short-interest ratio is presently 0.4 days.

Tema Oncology ETF Price Performance

CANC traded up $0.05 on Tuesday, hitting $27.93. The company had a trading volume of 3,603 shares, compared to its average volume of 6,994. The stock has a market cap of $48.60 million, a price-to-earnings ratio of 26.86 and a beta of 1.11. The company’s fifty day moving average price is $28.69 and its 200 day moving average price is $27.96. Tema Oncology ETF has a 1-year low of $21.47 and a 1-year high of $30.11.

Institutional Trading of Tema Oncology ETF

A hedge fund recently bought a new stake in Tema Oncology ETF stock. Thrivent Financial for Lutherans purchased a new position in Tema Oncology ETF (NASDAQ:CANC) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm purchased 319,376 shares of the company’s stock, valued at approximately $8,616,000. Thrivent Financial for Lutherans owned about 19.01% of Tema Oncology ETF at the end of the most recent reporting period.

About Tema Oncology ETF

The Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.